A day after settling with two of seven drugmakers seeking to advance generic challenges to its top-selling product, Xyrem, Jazz Pharmaceuticals plc moved to acquire Alizé Pharma II, the developer of a pegylated recombinant L-asparaginase program that could bolster Jazz's second largest commercial program, Erwinaze.